SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-17-000639
Filing Date
2017-02-01
Accepted
2017-02-01 07:30:42
Documents
4
Period of Report
2017-02-01
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 2.06: Material Impairments
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT opxa_8k.htm 8-K 45758
2 ASSIGNMENT AND ASSUMPTION OF LEASE opxa_ex101.htm EX-10.1 19411
3 PRESS RELEASE opxa_ex991.htm EX-99.1 11915
4 IMAGE opxa_ex991000.jpg GRAPHIC 5826
  Complete submission text file 0001654954-17-000639.txt   87047
Mailing Address 2635 TECHNOLOGY FOREST BLVD. THE WOODLANDS TX 77381
Business Address 2635 TECHNOLOGY FOREST BLVD. THE WOODLANDS TX 77381 (281) 272-9331
Opexa Therapeutics, Inc. (Filer) CIK: 0001069308 (see all company filings)

IRS No.: 760333165 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33004 | Film No.: 17563076
SIC: 2834 Pharmaceutical Preparations